Profile
Emily Ladd-Kravitz is co-chair of the firm’s Venture Capital & Emerging Technology Group and focuses her practice on complex corporate transactions and representation of private companies in all stages of their life cycle. She represents venture capital funds, private equity firms, other institutional investors and companies in connection with a wide variety of corporate and transactional matters, including mergers and acquisitions, private placements, minority investments, venture capital financings and corporate governance matters. She also advises start-up and growth-stage companies in all industries, including technology, edtech, medical device, clean energy, sustainable solutions and life sciences.
Concentrations
- Mergers and acquisitions
- Venture capital
- Private equity
- Corporate governance
- Business counseling
Capabilities
Experience
- Represented high-performance textile manufacturing company in sale to strategic buyer.
- Represented Earth Networks, Inc. in the sale of its WeatherBug Consumer Business to xAd, Inc. Earth Networks has the largest network in the world for weather, lightning and greenhouse gas monitoring.
- Represented insurance managing agent in $123M sale to private equity buyer.°
- Represented telecommunications client in its acquisition of an enterprise cloud management and services company.°
- Represented education services company in a private equity buyout and management rollover.°
- Represented manufacturing company in $150M sale to strategic buyer.°
- Represented insurance managing agent in $150M sale to private equity buyer.°
- Represented public company in retail industry in merger with a private equity backed company.°
- Represented technology company and defense contractor in merger with a strategic buyer.°
- Represented US and European magnetic solutions company in sale to private equity buyer.°
- Represented US security research and testing service company in sale to UK technology security company.°
- Represented global information management company in cross-border acquisition of US technology company.°
- Represented mobile payment solutions technology company in sale to strategic buyer.°
- Representation of venture capital fund in $115M Series C financing in biotechnology company.
- Representation of venture capital fund in Series B-3 investment in vegan food company.
- Representation of venture capital fund in Series B investment in visual arts technology company.
- Representation of venture capital fund in Series A investment in a consumer technology company building a peer-to-peer marketplace of campsites on privately-owned land.
- Representation of venture capital fund in $300M Series C financing of a Massachusetts-based insurance start-up.
- Representation of venture capital fund in $140M Series C financing in a leading payroll, benefits and HR technology platform.
- Representation of venture capital fund in convertible note financing in a company that provides a fully managed charging solution for electric vehicles in municipal and commercial fleets.
- Representation of venture capital fund in Series A Financing of a sustainable custom home design and prefabrication company.
- Representation of a venture capital fund in its Series Seed investment in a financial technology company.
- Representation of an investor in a $15 million Series A venture capital financing round in an organic grocery delivery company.
- Representation of a California-based venture capital firm in various investment transactions.
- Represented multiple early-stage venture capital funds in venture capital financings and convertible debt financings in technology, healthcare and retail companies.
- Represented the Icahn School of Medicine at Mount Sinai in the spinout of patents and technology and formation of Amathus Therapeutics, Inc., which will focus on the treatment of diseases and disorders caused primarily by lysosomol dysfunction.
- Represented New Enterprise Associates in a $44 million preferred stock financing of Annexon Biosciences, a biopharmaceutical company that develops therapeutic solutions to treat neurodegenerative disorders.
- Represented education-focused venture capital fund in multiple Series A and Series B financings.°
- Represented fitness technology company in convertible debt and venture capital financings.°
- Represented water management solutions company in convertible debt and venture capital financings.°
- Represented the lead institutional investor in the CMPO of common stock by Cascadian Pharmaceuticals, Inc. ($82.5 million).
- Represented underwriters in secondary public offering of China-based clean energy company’s $33M offering.°
°The above representations were handled by Ms. Ladd-Kravitz prior to her joining Greenberg Traurig, LLP.
Recognition & Leadership
- Listed, Chambers USA Guide, 2022-2024
- Private Equity: Venture Capital Investment, 2022-2024
- Startups & Emerging Companies, 2024
- Listed, Legal 500 United States, M&A/Corporate and Commercial - Venture Capital and Emerging Companies, 2021-2024
- "Recommended Lawyer," 2023-2024
- Listed, Boston magazine, "Top Lawyers - Corporate Law," 2022-2023
- Listed, Super Lawyers magazine, Massachusetts Super Lawyers, “Rising Stars,” 2017-2023
- Massachusetts Women's Edition, "Rising Stars," 2018-2020
- Listed, Massachusetts Lawyers Weekly, "Excellence in the Law: Up & Coming Lawyer," 2018
- Member, Boston Bar Association
- Member, Recently Elected Partners Forum Steering Committee
- Secretary, TiE Boston Board, 2018-Present
- Member, Massachusetts Bar Association
Credentials
Education
- J.D., Boston University School of Law, 2008
- B.A., summa cum laude, University of Arizona, 2005
Admissions
- Massachusetts